Stryker Cuts 2026 Outlook As Cyberattack, SAP Rollout And Hip And Knee Slowdown Hit Sales
Stryker cut 2026 organic growth guidance to 6.5–7% as softer hip and knee procedure trends, vascular supply constraints and caution on capital execution weighed on results. A cyberattack and SAP rollout clouded its view; management points to 2027 launches to grow at the high end of its markets.
Medtech Insight - October 30, 2026

After A Long Wait, Xbrane Gets FDA Approval For Lucentis Biosimilar
Following a multitude of setbacks, Xbrane Biopharma has finally announced FDA approval for Lucamzi (ranibizumab-blrz), its Lucentis biosimilar.
Generics Bulletin - October 30, 2026

Boehringer Lines Up Phase III Trial For Verducatib In COPD
Boehringer gets set to test whether targeting neutrophils can curb COPD exacerbations.
Scrip - October 30, 2026

Dexcom Plays Down PBM Contract Loss, Readies ‘Dexcom Direct’ To Steer Patients To Medical Benefit
Dexcom said losing preferred status on a pharmacy benefit manager (PBM) formulary affects less than 4% of US revenue and should have a limited effect on 2027 results. It plans to launch a patient access service, originally built for Medicare coverage expansion, early next year.
Medtech Insight - October 30, 2026

BsUFA IV Facility Lifecycle Program Aims To Cut Biosimilar CRLs Through Earlier FDA Dialogue
The new US FDA facility lifecycle program under BsUFA IV will let biosimilar sponsors discuss manufacturing risks before submission and after inspection, with the goal of preventing facility-related complete response letters.
Generics Bulletin - October 30, 2026

AstraZeneca Trims Costs To Support Pipeline Ambitions
The company is keeping a tight grip on costs as it seeks to reach its goal of $80bn in revenues by 2030.
Scrip - October 30, 2026

Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - October 30, 2026

Big Pharma, Domestic Firms Feel India’s Cancer Drug Trade Margin Cap Squeeze Differently
MNCs cut prices on 23% and Indian firms on 90% of their listings in a document released by India's National Drug Pricing Authority (NPPA) on Oct. 28 after the regulator's directive to limit trade margins to 30% of MRP on 137 non-scheduled oncology drugs. Scrip dissects the data and the logic.
Scrip - October 30, 2026

Lilly Boosts Alzheimer’s Pipeline With Blood And Speech Diagnostics
Sales growth for the pharma giant's Alzheimer's drug proves that blood biomarkers provide business benefits in this difficult area.
Medtech Insight - October 30, 2026

The Shift Toward Precision Immunology in Rheumatology Trials
How biomarker-driven strategies are reshaping patient selection, trial design and clinical development in autoimmune disease.
In Vivo - October 30, 2026

Sanofi On Lookout For Late-Stage Assets As Q3 Sales Climb
The French drugmaker has a BD war chest of around €20bn-€25bn and is keen to bring in assets fast
Scrip - October 30, 2026

Ophthalmology Has A Long History With AI, But Sees Modern Challenges
The AI ophthalmology market could be worth $1.3bn by 2030 as diagnosis, drug discovery and surgery all benefit from decades of innovation.
In Vivo - October 30, 2026

Unilever’s Dove, Vaseline Led Q3 US Growth As Wellbeing Stumbled
Dove and Vaseline led Unilever’s US growth in the third quarter, but Wellbeing dragged North America down 0.7%.
HBW Insight - October 30, 2026